JP2017535569A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535569A5 JP2017535569A5 JP2017527621A JP2017527621A JP2017535569A5 JP 2017535569 A5 JP2017535569 A5 JP 2017535569A5 JP 2017527621 A JP2017527621 A JP 2017527621A JP 2017527621 A JP2017527621 A JP 2017527621A JP 2017535569 A5 JP2017535569 A5 JP 2017535569A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharmaceutically acceptable
- acceptable salt
- riluzole
- ibudilast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 23
- ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 claims 14
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 14
- 229960002491 ibudilast Drugs 0.000 claims 14
- 229960004181 riluzole Drugs 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 11
- 208000015122 neurodegenerative disease Diseases 0.000 claims 10
- 230000004770 neurodegeneration Effects 0.000 claims 9
- 230000000750 progressive effect Effects 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 6
- 208000033808 peripheral neuropathy Diseases 0.000 claims 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 5
- 230000001684 chronic effect Effects 0.000 claims 5
- 239000002552 dosage form Substances 0.000 claims 5
- 201000001119 neuropathy Diseases 0.000 claims 5
- 230000007823 neuropathy Effects 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 206010003694 Atrophy Diseases 0.000 claims 3
- 208000001089 Multiple system atrophy Diseases 0.000 claims 3
- 206010033799 Paralysis Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 230000037444 atrophy Effects 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 3
- 208000010118 dystonia Diseases 0.000 claims 3
- 208000028867 ischemia Diseases 0.000 claims 3
- 239000008297 liquid dosage form Substances 0.000 claims 3
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 3
- 206010003591 Ataxia Diseases 0.000 claims 2
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 2
- 206010010356 Congenital anomaly Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000014094 Dystonic disease Diseases 0.000 claims 2
- 206010017065 Foster-Kennedy Syndrome Diseases 0.000 claims 2
- 208000024412 Friedreich ataxia Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 2
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 2
- 206010028570 Myelopathy Diseases 0.000 claims 2
- 206010036105 Polyneuropathy Diseases 0.000 claims 2
- 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 claims 2
- 208000005392 Spasm Diseases 0.000 claims 2
- 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 claims 2
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 208000016620 Tourette disease Diseases 0.000 claims 2
- 208000018839 Wilson disease Diseases 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 230000003412 degenerative effect Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 201000004815 juvenile spinal muscular atrophy Diseases 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000031237 olivopontocerebellar atrophy Diseases 0.000 claims 2
- 201000002241 progressive bulbar palsy Diseases 0.000 claims 2
- 208000032527 type III spinal muscular atrophy Diseases 0.000 claims 2
- 206010008027 Cerebellar atrophy Diseases 0.000 claims 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 208000005819 Dystonia Musculorum Deformans Diseases 0.000 claims 1
- 208000005189 Embolism Diseases 0.000 claims 1
- 208000027776 Extrapyramidal disease Diseases 0.000 claims 1
- 206010016212 Familial tremor Diseases 0.000 claims 1
- 208000025329 Fazio-Londe disease Diseases 0.000 claims 1
- 208000001799 Hereditary Optic Atrophies Diseases 0.000 claims 1
- 102000016871 Hexosaminidase A Human genes 0.000 claims 1
- 108010053317 Hexosaminidase A Proteins 0.000 claims 1
- 102000016870 Hexosaminidase B Human genes 0.000 claims 1
- 108010053345 Hexosaminidase B Proteins 0.000 claims 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 206010023201 Joint contracture Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 208000010428 Muscle Weakness Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 240000007817 Olea europaea Species 0.000 claims 1
- 208000002774 Paraproteinemias Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 102000019197 Superoxide Dismutase Human genes 0.000 claims 1
- 108010012715 Superoxide dismutase Proteins 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010044074 Torticollis Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims 1
- 208000010399 Wasting Syndrome Diseases 0.000 claims 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 1
- 102000001307 androgen receptors Human genes 0.000 claims 1
- 108010080146 androgen receptors Proteins 0.000 claims 1
- 210000003403 autonomic nervous system Anatomy 0.000 claims 1
- 208000018300 basal ganglia disease Diseases 0.000 claims 1
- 208000025434 cerebellar degeneration Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000009028 early myoclonic encephalopathy Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000006517 essential tremor Diseases 0.000 claims 1
- 208000019995 familial amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 claims 1
- 230000001969 hypertrophic effect Effects 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 206010023497 kuru Diseases 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 231100000518 lethal Toxicity 0.000 claims 1
- 230000001665 lethal effect Effects 0.000 claims 1
- 210000002161 motor neuron Anatomy 0.000 claims 1
- 206010065579 multifocal motor neuropathy Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000001338 necrotic effect Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 230000002232 neuromuscular Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 208000021090 palsy Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 238000005096 rolling process Methods 0.000 claims 1
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims 1
- 230000035807 sensation Effects 0.000 claims 1
- 230000001953 sensory effect Effects 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000003755 striatonigral degeneration Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 208000018724 torsion dystonia Diseases 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462084879P | 2014-11-26 | 2014-11-26 | |
| US62/084,879 | 2014-11-26 | ||
| PCT/US2015/062456 WO2016085998A1 (en) | 2014-11-26 | 2015-11-24 | Combination of ibudilast and riluzole and methods of using same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017535569A JP2017535569A (ja) | 2017-11-30 |
| JP2017535569A5 true JP2017535569A5 (enExample) | 2019-01-10 |
| JP6827924B2 JP6827924B2 (ja) | 2021-02-10 |
Family
ID=56074979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017527621A Active JP6827924B2 (ja) | 2014-11-26 | 2015-11-24 | イブジラスト及びリルゾールの組み合わせを含む医薬および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10258611B2 (enExample) |
| EP (1) | EP3223815B1 (enExample) |
| JP (1) | JP6827924B2 (enExample) |
| KR (1) | KR102462638B1 (enExample) |
| CN (1) | CN107205986A (enExample) |
| BR (1) | BR112017010700A2 (enExample) |
| CA (1) | CA2967826C (enExample) |
| ES (1) | ES2891306T3 (enExample) |
| WO (1) | WO2016085998A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021530543A (ja) * | 2018-07-22 | 2021-11-11 | バイオヘイブン・セラピューティクス・リミテッドBiohaven Therapeutics Ltd. | アルツハイマー病を処置するためのリルゾールプロドラッグの使用 |
| MX2021001563A (es) * | 2018-08-16 | 2021-06-15 | Biohaven Therapeutics Ltd | Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades. |
| JP7430719B2 (ja) * | 2018-10-19 | 2024-02-13 | メディシノバ・インコーポレイテッド | イブジラストを用いて眼疾患／障害または損傷を治療する方法 |
| WO2021055890A1 (en) * | 2019-09-20 | 2021-03-25 | Icahn School Of Medicine At Mount Sinai | Controlled release formulations of riluzole and their uses |
| EP4240308A4 (en) * | 2020-10-05 | 2024-10-30 | Icahn School of Medicine at Mount Sinai | Riluzole for the treatment of alzheimer's disease |
| CN117940128A (zh) | 2021-07-26 | 2024-04-26 | 美迪诺亚公司 | 异丁司特用于防止眼癌转移 |
| US12042485B2 (en) | 2021-10-07 | 2024-07-23 | Medicinova, Inc. | Methods of minimizing cancer metastasis |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2585246A1 (fr) | 1985-07-26 | 1987-01-30 | Cortial | Procede d'obtention de formes pharmaceutiques solides a liberation prolongee |
| US4788055A (en) | 1985-12-09 | 1988-11-29 | Ciba-Geigy Corporation | Resinate sustained release dextromethorphan composition |
| GB8613689D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB8613688D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| US4816264A (en) | 1986-06-06 | 1989-03-28 | Warner-Lambert Company | Sustained release formulations |
| US4996047A (en) | 1988-11-02 | 1991-02-26 | Richardson-Vicks, Inc. | Sustained release drug-resin complexes |
| CA2002492A1 (en) | 1988-11-11 | 1990-05-11 | Sandra T. A. Malkowska | Pharmaceutical ion exchange resin composition |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| WO2000074676A1 (en) | 1999-06-04 | 2000-12-14 | Vereniging Voor Christelijk Wetenschappelikjk Onderwijs | Use of riluzole for the treatment of multiple sclerosis |
| WO2004105756A2 (en) | 2003-05-29 | 2004-12-09 | Novartis Ag | Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof |
| AU2005218625A1 (en) * | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
| BRPI0518829A2 (pt) | 2004-12-06 | 2008-12-09 | Avigen Inc | mÉtodo para o tratamento de dor neuropÁtica e sÍndromes associadas |
| CA2970273C (en) | 2007-07-11 | 2020-04-14 | Medicinova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
-
2015
- 2015-11-24 CA CA2967826A patent/CA2967826C/en active Active
- 2015-11-24 BR BR112017010700A patent/BR112017010700A2/pt not_active Application Discontinuation
- 2015-11-24 CN CN201580064290.9A patent/CN107205986A/zh active Pending
- 2015-11-24 JP JP2017527621A patent/JP6827924B2/ja active Active
- 2015-11-24 US US15/527,280 patent/US10258611B2/en active Active
- 2015-11-24 WO PCT/US2015/062456 patent/WO2016085998A1/en not_active Ceased
- 2015-11-24 KR KR1020177015476A patent/KR102462638B1/ko active Active
- 2015-11-24 EP EP15863670.4A patent/EP3223815B1/en active Active
- 2015-11-24 ES ES15863670T patent/ES2891306T3/es active Active
-
2019
- 2019-02-28 US US16/289,636 patent/US20200030301A1/en not_active Abandoned
-
2020
- 2020-06-18 US US16/904,911 patent/US11278531B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017535569A5 (enExample) | ||
| JP7627514B2 (ja) | Ｒ－ケタミンおよびその塩の医薬品としての応用 | |
| JP2021075556A5 (enExample) | ||
| Peng et al. | The anti-depression effect of Xylaria nigripes in patients with epilepsy: A multicenter randomized double-blind study | |
| BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| RU2003124059A (ru) | Лечение неврологической дисфункции с применением сульфаматов фруктопиранозы и эритропоэтина | |
| JP2005501801A5 (enExample) | ||
| WO2016190780A1 (en) | Extracellular dna as a therapeutic target in neurodegeneration | |
| WO2021165472A1 (en) | Masitinib for the treatment of a multiple sclerosis patient subpopulation | |
| Chaves et al. | Functional neuroimaging of minocycline's effect in a patient with schizophrenia | |
| JP2017513845A5 (enExample) | ||
| Yeh | Current therapeutic options in pediatric multiple sclerosis | |
| Specchio et al. | Efficacy of levetiracetam in the treatment of drug-resistant Rett syndrome | |
| Geng et al. | Clinical neurorestorative progress in multiple sclerosis | |
| Gilhuis et al. | Demyelinating polyneuropathy in Leber hereditary optic neuropathy | |
| NO20090814L (no) | N-fenyl-prenylamin derivater for behandling av kognitive, neurodegenerative eller neurone sykdommer eller lidelser | |
| Kelemen et al. | Lecithin is not effective in amyotrophic lateral sclerosis | |
| BRPI0517460A (pt) | análogos canabinóides eficazes de administração oral | |
| Smith et al. | Inhibitory motor status: two new cases and a review of inhibitory motor seizures | |
| Kumar et al. | Vitamin A, C, D, E and B12 levels in leprosy: a case control study | |
| JP6839076B2 (ja) | 変形性関節症の治療のためのネリドロン酸またはその塩の使用 | |
| RU2013139704A (ru) | Применение белка yb-1 и его фрагментов для изготовления лекарственных средств при лечении болезни альцгеймера | |
| Moore et al. | Clinical aspects of motor neurone disease | |
| Chinthapalli | Pharmacological treatment | |
| Shevchenko | Neglect Syndrome in Hemisphere Stroke |